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a b s t r a c t
Traumatic spinal cord injury (SCI) represents oneof themost disabling injuries of thehumanbody causing
temporary or permanent sensory and/or motor system deﬁcit, particularly hind limb locomotor function
impairment. At present, steroidal inﬂammatory drugs, in particular methylprednisolone sodium succi-
nate (MPSS) are the ﬁrst line choice treatment of acute SCI. Despite progress in pharmacological, surgical
and rehabilitative treatment approaches, SCI still remains a very complex medical and psychological
challenge, with no curative therapy available. The aim of the present study was to compare the efﬁcacy
ofMPSS in respect to other GCs such as dexamethasone (Dex) andmometasone furoate (MF) in an in vitro
suitable model of LPS-induced inﬂammation in J774 cells as well as in an in vivo experimental mouse SCI
(compression model). In both the in vitro and in vivo experiments, MF resulted surprisingly more potent
than Dex and MPSS. In detail, mice sacriﬁced seven days after induction of SCI trauma resulted not only
in tissue damage, cellular inﬁltration, ﬁbrosis, astrocyte activation, iNOS expression, extracellular signal
regulated kinase 1/2 phosphorylation in injured tissue, poly (ADP-ribose) polymerase 1 (PARP-1) activa-
tion but also apoptosis (Bax and Bcl-2 expression). All three GCs demonstrated the ability to modulate
inﬂammatory, oxidative as well as apoptotic pathways, but MF demonstrated the best efﬁcacy, while
Dex and MPSS showed alternative potency with a different degree of protection. Therefore, we can con-
clude that MF is the best candidate for post-traumatic chronic treatment, since it ameliorates different
molecular pathways involved in the damage’s propagation to the surrounding areas of the injured spinal
cord.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
In reference to thoracolumbar spinal trauma, better known as
Spinal Cord Injury (SCI), wemean all those events of traumatic and
non-traumatic origin that affect central nervous system (CNS) and
create disability with temporary or permanent deﬁcit of sensory
and/or motor system, in particular hind limb locomotor function
[1]. Car and motorcycle accidents (50%), falls (43%) and sporting
Abbreviations: SCI, Spinal cord injury;MPSS, methylprednisolone sodium succi-
nate; Dex, dexamethasone; MF, mometasone furoate; CNS, central nervous system;
GCs, glucocorticoids; GR, glucocorticoid receptor; pERK1/2, extracellular signal reg-
ulated kinase 1/2; GILZ, glucocorticoid-induced leucine zipper gene; GFAP, glial
ﬁbrillary acidic protein; PARP-1, poly (ADP-ribose) polymerase 1.
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injuries (7%) are the main causes of trauma [2], while malignant
spinal cord compression due to cancer, arthritis, osteoporosis and
inﬂammation represent the etiology for non-traumatic SCI that
results overall in 54% of spinal stenosis and 26% of tumors [3]. In
any cases, SCI affects style and quality of life as well as survival [4].
For this reason, SCI can be considered a widespread problem with
high costs for national health systems.
The ﬁrst steps in SCImanagement consist of patient immobilisa-
tion, spinal cord decompression and stabilization. Surgery in early
stages is used to remove bone fragments, foreign objects, herniated
disks or fractured vertebrae compressing the spine but it can also
be deemed necessary in preventing pain or deformities. However,
case by case evaluation is necessary because these procedures are
athigh riskof further complications [5]. Physiotherapy is frequently
associated with pharmacological treatment.
SCImanagementmainly consists in avoidingprogressivedegen-
eration and extension of damage, counteracting the secondary
http://dx.doi.org/10.1016/j.phrs.2015.07.013
1043-6618/© 2015 Elsevier Ltd. All rights reserved.
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injury at the perilesional area, in order to relieve pain and
symptoms, and restore functional motor ability [6]. Furthermore,
secondary injury observed in SCI is sustained by an inﬂammatory
response through the activation of the innate immune response
and, in particular, through the activation of macrophages [7,8].
Glucocorticoids (GCs) are steroid hormones regulated by the
hypothalamic-pituitary-adrenal axis [9]. By binding to glucocor-
ticoid receptor (GR), almost ubiquitously expressed, GCs become
pleiotropic regulators of multiple cell types, with a wide range
of roles in both healthy and diseased individuals [10], assuming
a critical role in physiological systems [11].
Acute SCI involves the adoption of steroidal anti-inﬂammatory
drugs. In particular, to date, methylprednisolone sodium succinate
(MPSS) is considered the ﬁrst line treatment.
MPSS is a synthetic glucocorticoid, the only FDA-approved ther-
apeutic agent recognized as standard care in acute SCI treatment.
Early treatment with MPSS within an 8 hour time period after
injury [12], is demonstrated to reduce severe edema develop-
ment as well as to preserve spinal cord architecture at damage
site [13]. Pharmacological management prescribes 30mg/kg MPSS
intravenously as a bolus, followed by 5.4mg/Kg/hour intravenous
infusion for 24–48h [14,15]. Nevertheless, side-effects, such as sep-
sis, bronchopneumonia, gastrointestinal haemorrhage [16], wound
infection and psychological neurosis following high doses of MPSS
administration can occur [17]. Today, the main goal of researchers
is an effective pharmacological treatment useful in the repair of
spinal damage together with the prevention of secondary effects.
The aim of the present work was to test the efﬁcacy of three
different GCs performing both an in vitro suitable model of inﬂam-
mation which characterizes SCI (speciﬁcally, J774 macrophages
stimulated with lipopolysaccharide) and an in vivo model of SCI
in mice.
In detail, the study was designed to compare the convention-
ally used MPSS efﬁcacy with the possible therapeutic properties
of mometasone furoate (MF), a synthetic GC typically prescribed
for topical applications in chronic hand eczema [18] and airway
inﬂammation management of asthma [19], and dexamethasone
(Dex), another synthetic corticosteroid commonly used as anti-
inﬂammatory, immunosuppressive as well as anti-shock drug [20]
in SCI lesions.
Achieved results have shown the peculiarity of each pharma-
cological treatment. Surprisingly, MF was the most effective in
counteracting chronic degeneration at level of the perilesional area,
demonstrating the capability tomodulate different signalling path-
ways.
2. Materials and Methods
2.1. GC treatments
Both in vitro and in vivo studies were performed testing the
concentration of three different GCs, in particular:
Glucocorticoid Chemical name in vivo tested Dosage
MPSS C22H30O5
1S,2R,8S,10S,11S,14R,15S,17S)-
14,17-didroxi-14-(2-idroxiacetil)-
2,8,15-
trimetitetraciclo[8.7.0.02,7.011,15]eptadeca-
3,6-dien-5-one
6mg/Kg, 5% DMSO, ip
Dex C22H29FO5
(9-ﬂuoro-11,17,21-tridrossi-16a-
metilpregna-1,4-diene-3,20-dione)
1mg/Kg, ip
MF C27H30Cl2O6
9,21-dichloro-11,17-dihydroxy-
16-methylpregna-1,4-diene-
3,20-dione
17-(2-furoate)
0.1mg/Kg,5% DMSO, ip
The dose of MPSS used in the clinical practice is currently
30mg/Kg [14,15], that results to high for in vivomice chronic treat-
ment. For this reason, we have set experimentally and empirically
the effective dosage ofMPSS deﬁning the concentration of 6mg/Kg.
The dose of other GCs has been scaled based on their relative
potency compared to MPSS.
2.2. In vitro study
2.2.1. J774 cells
The murine monocyte/macrophage J774 cell line was grown in
Dulbecco’s modiﬁed Eagles medium (DMEM) supplemented with
2mMglutamine, 25mMHepes, penicillin (100U/ml), streptomycin
(100g/ml), 10% foetal bovine serum (FBS) and 1.2% Na pyru-
vate. Cells were plated in 24-well culture plates at a density of
2.5±105 cells/ml or in 60 mm-diameter culture dishes (3±106
cells per 3ml dish) and allowed to adhere at 37 ◦C in 5% CO2. After
24h, cells were pre-treated (for 2h) with increasing concentration
of old (Dex and MET) and new (MF), and stimulated with LPS from
Escherichia coli, Serotype 0111:B4, (10g/ml). After 24h of treat-
ment, the supernatants were collected for nitrite measurement.
2.2.2. Nitrite measurement
The nitrite concentration in the samples was measured by
the Griess reaction, by adding 100l of Griess reagent (0.1%
naphthylethylenediamide dihydrochloride in H2O and 1% sul-
phanilamide in 5% concentratedH2PO4; vol. 1:1) to 100l samples.
The optical density at 540nm (OD540) was measured using
microplate reader (Multiskan 60, Thermo Scientiﬁc). Nitrite con-
centration was calculated by comparison with OD540 of standard
solutions of sodium nitrite prepared in culture medium.
2.2.3. iNOS and COX-2 expression
The analysis of iNOS, COX-2, -tubulin and -actin in J774
macrophages were performed on whole cell lysates. After stimula-
tion with LPS for 24h, cells were washed with cold PBS and lysed
for 10min at 4 ◦C with a lysis buffer (20mM HEPES, 1.5mM MgCl2,
400mM NaCl, 1mM EDTA, 1mM ECTA, 1mM DTT, 0.5mM PMSF,
15g/ml soybean trypsin inhibitor, 3g/mlpepstatin, 2g/ml leu-
peptin, 40M benzamidine, 50mM NaF, 1% Nonidet P-40 and 20%
glycerol). Lysates from adherent cells were collected by scraping
and centrifuged at 12,000×g for 15min at 4 ◦C. The supernatants
were collected and protein concentration in cell lysates was deter-
mined by Bio-Rad Protein Assay (Bio-Rad).
Equal amounts of proteins were mixed with gel loading buffer
(250mMTris, 8%SDS,40%glycerol, 20%2-mercaptoethanol, 1%bro-
mophenol) in a ratio of 1:4, boiled and centrifuged at 10,000×g
for 10min. Each sample was loaded and electrophoresed on a
10% SDS-polyacrylamide gel. The proteins were transferred on to
nitrocellulose membranes (Protran Amersham). The membranes
were blocked with 0.1% TBS-Tween containing 5% BSA for iNOS,
with 1% PBS-Tween containing 3% non-fat dry milk for COX-2 and
with 0.1% PBS-Tween containing 5% non-fat dry milk for -tubulin
and -actin. After the blocking, the membranes were incubated
with the relative primary antibody overnight at 4 ◦C. Rabbit mono-
clonal antibody anti iNOS (Cell Signaling) was diluted 1:1000 in
0.1% TBS-Tween, containing 5% BSA; mouse monoclonal antibody
anti COX-2 was diluted 1:1000 in 0.1% PBS-Tween containing 3%
non-fat dry milk; mouse monoclonal antibodies anti -actin and
-tubulin (Santa Cruz Biotecnology) were diluted 1:1000 in 0.1%
PBS-Tween containing 5% BSA. After incubation, the membranes
were washed six times with 0.1% TBS-Tween or 0.1% PBS-Tween
and incubated for 1.5h at room temperature with horseradish
peroxidase-conjugated anti-rabbit and anti-mouse secondary anti-
bodies (Santa Cruz Biotecnology) diluted 1:5000 and1:2000 in 0.1%
TBS/Tween containing 5% BSA and 0.1% PBS-Tween containing 5%
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Fig. 1. Dex, MPSS andMF effects on nitrite production in LPS-treated J774macrophages. Cells were pre-treatedwith Dex, MPSS andMF: a) (0.01, 01, 1 and 10M) andMF: b)
(0.0001, 0.001 and 0.01M) or vehicle (DMSO 0.5%) for 2h and further incubated for 24hwith LPS (10g/ml). At the end of incubation (24h), the supernatant were collected
for the nitrite measurement by the Griess reaction. Data are expressed as means± SEM from n=3 independent experiments performed in triplicates, each. ◦◦◦p<0.001 vs
unstimulated cells (control); *p<0.05 and ***p<0.001 vs LPS+DMSO.
non-fat dry milk, respectively. Following incubation, membranes
were washed and developed using ImageQuant-400 (GE Health-
care, USA).
2.3. In vivo study
2.3.1. Animals
Male adult CD1 mice (25–30g weight) were purchased from
Harlan (Milan, Italy). Animals were housed in individually ven-
tilated cages with food and water ad libitum. The room was
maintained at a constant temperature and humidity on a 12h/12h
light/dark cycle.
Animal care was in compliance with Italian regulations on
protection of animals used for experimental and other scientiﬁc
purposes (D.M. 116/92) as well as with the EEC regulations (O.J. of
E.C.L 358/1 12/18/1986).
2.3.2. SCI induction
After anaesthesia, induced with an anesthetic cocktail com-
posedof tiletamine (100mg/Kg) plus xylazine (15mg/Kg; 10ml/Kg,
i.p), mice were subjected to SCI, according to the model described
by Rivlin and Tator [21].
A longitudinal incision was made on the midline of the back,
exposing the paravertebral muscles. These muscles were dissected
exposing T5–T8 vertebrae. The spinal cord was exposed via a four-
level T5–T8 laminectomy and SCI was produced by extradural
compression of the spinal cord at level T6–T7 using an aneurysm
clipwith a closing force of 24g. In all injured groups, the spinal cord
was compressed for 1min.
Following surgery, 1ml of saline was administered subcuta-
neously in order to replace the blood volume lost during the
surgery. The induced damage was veriﬁed, after the animals
were awaked, evaluating the mobility of the hind limbs on a ﬂat
surface.
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Fig. 2. Dex MPSS and MF effects on iNOS expression in LPS-treated J774 macrophages. Cells were pre-treated with Dex, MPSS and MF (0.01, 01, 1 and 10M) or vehicle
(DMSO 0.5%) for 2h and further incubated for 24h with LPS (10g/ml). Equal amounts of whole lysates were fractionated by 10% SDS–PAGE and subjected to Western
blot analysis. Data are expressed as means± SEM from n=2 independent experiments performed in triplicates, each. ◦◦◦p<0.001 vs unstimulated cells (control); *p<0.05,
**p<0.01 and ***p<0.001 vs LPS+DMSO.
2.3.3. Experimental design
Mice were randomly allocated into the following groups (n=60
total animals):
Sham group (n=5): Mice not subjected to SCI but only to T5–T8
vertebrae exposition, sacriﬁced as control.
SCI group (n=10): Mice were subjected to surgical operations
to induce SCI and injected with saline;
SCI+MF (n=10): Mice were subjected to surgical operations to
induce SCI and treated with MF 0.1mg/Kg;
SCI+Dex (n=10): Mice were subjected to surgical operations to
induce SCI and treated with Dex 1mg/Kg;
SCI+MPSS (n=10): Mice were subjected to surgical operations
to induce SCI and treated with MPSS 6mg/Kg.
In another experimental set, investigated drugs were prelimi-
nary tested in order to evaluate a more efﬁcient dosage. Moreover,
control groups (not included in the present work) designed as
“Sham+MF” (n=5), “Sham+Dex” (n=5), “Sham+MPSS” (n=5),
“Sham+vehicle (5% DMSO)” (n=5) were tested to evaluate toxicity
of GC as well as vehicle (DMSO) injection.
Mice were treated i.p. 30min following trauma induction and
once a day for 7 days until sacriﬁce.
Spinal cord area, corresponding to the thoracic spine, was sam-
pled, in order to evaluate the various parameters.
2.3.4. May-Grunwald Giemsa staining
Spinal cord biopsies, taken at 7 days following trauma, were
ﬁxed in 10% (w/v) PBS-buffered formaldehyde. Tissue segments
containing the lesion were parafﬁn-embedded and cut into 7m-
thick sections. Tissue sections were deparafﬁnized with xylene,
stained with May-Grunwald Giemsa solution for tissue sections
(Bio Optica, Milan, Italy) according to manufacturer’s protocol and
studied using light microscopy (LEICA ICC50HD microscope).
2.3.5. Immunohistochemical localization
Seven-m sections, prepared from parafﬁn-embedded tissue,
were deparafﬁnated and endogenous peroxidase was quenched
with0.3% (v/v) hydrogenperoxide in60% (v/v)methanol for 30min.
Nonspeciﬁc adsorptionwasminimized by incubating the section in
2% (v/v) normal goat serum in PBS for 20min. Endogenous biotin
or avidin binding sites were blocked by sequential incubation for
15min with biotin and avidin (DBA, Milan, Italy), respectively.
Sections were incubated overnight with: anti-glial ﬁbrillary acidic
protein (GFAP) mouse monoclonal Ab (Cell Signaling Technology,
1:100); anti-iNOS rabbit polyclonal Ab (Santa Cruz Biotechnol-
ogy, 1:100); anti-poly (ADP-ribose) polymerase 1 (PARP-1) rabbit
polyclonal Ab (Santa Cruz Biotechnology, 1:100); anti-Bax rab-
bit polyclonal Ab (Santa Cruz Biotechnology, 1:100); anti-Bcl-2
rabbit polyclonal Ab (Santa Cruz Biotechnology, 1:100). Sections
were washed with PBS and incubated with secondary antibody.
Speciﬁc labelling was detected with a biotin-conjugated goat anti-
rabbit IgGandavidin-biotinperoxidase complex (DBA,Milan, Italy).
The counter-stain was developed with diaminobenzidine (brown
color) and ematossilin (blue background) or nuclear fast red (red
background). All images were acquired using in a LEICA ICC50HD
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Fig. 3. Dex MPSS and MF effects on COX-2 expression in LPS-treated J774 macrophages. Cells were pre-treated with Dex, MPSS (0.01, 01, 1 and 10M) and MF (0.01, 01 and
1M) or vehicle (DMSO 0.5%) for 2h and further incubated for 24h with LPS (10g/ml). Equal amounts of whole lysates were fractionated by 10% SDS–PAGE and subjected
to Western blot analysis. Data are expressed as means± SEM from n=2 independent experiments performed in triplicates, each. ◦◦◦p<0.001 vs unstimulated cells (control);
***p<0.001 vs LPS+DMSO.
light microscope. Quantitative data obtained through densitomet-
ric analysis were acquired using Leica Application Suite V4.2.0
software
2.3.6. Extracellular signal regulated kinase 1/2 (pERK1/2), PARP-1
and Bax expression
Protein content for speciﬁc antibodies was evaluated in the
spinal cord by SDS page electrophoresis and blotting according to
standardized protocol for spinal cord tissues [22].
Membraneswere probed at 4 ◦C overnightwith rabbit phospho-
p44/42MAPK (pERK1/2) (Cell Signaling Technology, 1:1000), rabbit
PARP-1 (Santa Cruz Inc, 1:200), rabbit Bax (Cell Signaling Tech-
nology, 1:500). Signal was developed following incubation with
horseradishperoxidase-conjugatedanti-rabbit (1:5000; SantaCruz
Biotecnology) for 1h at room temperature and using an enhanced
chemiluminescence system (Luminata Western HRP Substrates,
Millipore). p44/42 MAPK (ERK1/2) (Cell Signaling Technology,
1:1000) was used to normalize the signals of phospho-p44/42
MAPK, while -actin and GAPDH were used to normalized PARP-1
and Bax expression, respectively.
The protein bands were acquired with ChemiDocTM MP System
(Bio-Rad) and quantiﬁed using a computer program (ImageJ).
2.4. Statistical evaluation
The results are expressed as mean± standard error (SEM) of
the mean of n observations, where n represents the number of
experiments performed in different days or the number of animals.
For in vitro study triplicate wells were used for the various treat-
ment conditions. Data were analyzed in GraphPad Prism version
6.0 (GraphPad Software, La Jolla, CA). The results were analysed by
one-wayANOVA followedby aBonferronipost-hoc test formultiple
comparisons. A p value of <0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. In vitro study
3.1.1. Nitrite production and iNOS expression are strongly
inhibited by MF in LPS-stimulated J774 macrophages
NO pathway is activated during the inﬂammatory process that
characterizes the secondary injury of SCI. Although it iswell known
that GCs inhibit NO pathway, there is insufﬁcient data in support of
MPSS, the referencedrug for SCI treatment, andDexandMF. For this
reason, we evaluated the effects of these GCs on nitrite production
and iNOS expression in LPS-treated J774 macrophages.
LPS (10g/ml, 24h) treatment of J774 macrophages induced
a signiﬁcant increase of nitrite production in the cell medium
(p<0.001, n=3) in respect to unstimulated macrophages (control).
When Dex, MPSS (0.01, 0.1, 1 and 10M; Fig. 1a) and MF (0.01,
0.1, 1 and 10M in Fig. 1a and 0.0001, 0.001, 0.01 in Fig. 1b) were
added to J774 macrophages, 2h before LPS stimulation, a signiﬁ-
cant and concentration-dependent decrease of nitrite production
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Fig. 4. WBC inﬁltration in spinal cord tissue. May Grunwald Giemsa staining reveals that sham animals do not show presence of WBC inﬁltrate (a). Conversely, after seven
days, untreated SCI evoke lymphocyte and monocytic inﬁltration accompanied by ﬁbrotic tissue indicating (b). Total protection is evident in SCI-damage mice treated with
MF (c), while a lower capability to counteract cellular inﬁltrate and ﬁbrosis is assessed following treatments with Dex (d) and MPSS (e).
in cell medium was observed (Fig. 1a and b). In particular, MF was
more potent than Dex and MPSS. In fact, the IC50 were 0.061M,
0.53M and 0.00024M, for Dex, MPSS and MF, respectively.
To determine whether the different potency of these GCs on
LPS-induced nitrite production was mediated by the regulation of
iNOS protein expression, we evaluated the levels of iNOS protein in
whole lysates from J774 cells, stimulated with LPS and pre-treated
with test compounds, as described above. As shown in the Fig. 2,
MFwasmorepotent since it signiﬁcantly inhibited iNOSexpression
already at a 0.01M concentration whereas Dex became active at
0.1M and MPSS at 1M.
3.1.2. COX-2 expression are strongly inhibited by MF in
LPS-stimulated J774 macrophages
Since COX-2 expression is another enzyme activated in the
inﬂammatory response to secondary injury, its effects were also
compared to those of MPSS, Dex and MF. As observed for iNOS
expression, Dex, MPSS (0.01, 0.1, 1 and 10M) and MF (0.01,
0.1 and 1M) inhibited COX-2 expression in LPS-treated J774
macrophages (Fig. 3a, see densitometric analysis b). In particular,
MF was more potent than Dex and MPSS. In fact, the inhibition of
protein expression at 0.01M was 79% for MF and 39–34% for Dex
and MPSS, respectively.
3.2. In vivo study
3.2.1. GC treatments protect by white blood cell (WBC)
inﬁltration in SCI
SCI causes severe damage in mice both for mechanical injury
and for inﬁltrating cells at the site of injury.
While sham animals do not show presence of WBC (Fig. 4a),
seven days after spinal trauma induction, this condition is com-
pletely reversed in SCI damaged animals (Fig. 4b). Despite no
presence of eosinophil cells (pinkish–red basophile cytoplasm) is
observed in this animals, on the contrary, a marked and massive
CNS lymphocyte and monocyte inﬁltration, distributed homoge-
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Fig. 5. pERK1/2 is modulated by GC treatment, better than other by MF. pERK1/2 expression is signiﬁntly upregulated in SCI untreated mice comparing to sham animals (a).
Conversely, all GCs inhibit pERK1/2 activation, but only the MF inhibition results signiﬁcant (p<0.05) (a). (b) Normalized pERK1/2 expression on ERK 2 was graphed in the
showed densitometric analysis.*p<0.05.
neously in the perilesional tissue and accompanied by ﬁbrotic
tissue indicating damage in the adjacent areas has been seen.
Although treatment with Dex (Fig. 4d) and MPSS (Fig. 4e) protect
the spinal cord tissue by cellular inﬁltration and ﬁbrosis, there is a
complete andmore evident protection in SCI-damagemice treated
with MF (Fig. 4c).
In control groups, samples of spinal cord were designed to eval-
uate the possible toxic side-effects of GC injection. No pathological
condition was assessed following May-Grunwald Giemsa staining
when mice administered with MF, Dex and MPSS were compared
with sham animals (data not shown).
3.2.2. pERK1/2 expression is inhibited by MF treatment following
SCI
To investigate mechanisms of spinal cord degeneration, MAPK
pathway was evaluated.
Tissue samples of SCI untreated mice displayed a signiﬁca-
tive (p<0.05) increase of pERK1/2 expression in respect to sham
animals (Fig. 5a, see densitometric analysis b). Conversely, GCs
inhibited pERK1/2 activation, but only MF inhibition resulted sig-
niﬁcant (p<0.05) (Fig. 5a, see densitometric analysis b).
3.2.3. GFAP increased expression is strongly inhibited by MF
treatment following SCI
GFAP is considered a marker of astrocyte cells as well as of neu-
ronal damage.
Immunostaining for GFAP clearly demonstrated that SCI-
damagedmice (Fig. 6b) have anenhanced and signiﬁcant highGFAP
expressionwhen compared to shamanimals (p<0.0001, Fig. 6a, see
densitometric analysis Fig. 6f). Interestingly, all GC tested inhibited
GFAP expression (Fig. 6, see densitometric analysis Fig. 6f). Overall,
comparing the ability of GCs to avoid tissue expression of this indi-
rect marker of astrocyte activation, we established that SCI mice
treated with MF (Fig. 6c, see densitometric analysis Fig. 6f) dis-
played lower positivity for GFAP, followed by Dex (Fig. 6d, see
densitometric analysis Fig. 6f) and ﬁnally by MPSS (Fig. 6e, see
densitometric analysis Fig. 6f). The remarkable efﬁcacy of MF was
further conﬁrmed by a signiﬁcant difference between this GC and
SCI +Dex (p<0.01) as well as SCI +MPSS groups (p<0.01, for both
see densitometric analysis Fig. 6f).
3.2.4. GCs differently modulate iNOS expression following SCI
Radicalic species production has a key role in development of
severe spinal cord damage, especially following SCI.
During investigation of oxidative pathways, shammice resulted
negative for iNOS staining (Fig. 7a, see densitometric analysis
Fig. 7f). Analysis of samples of SCI mice demonstrated that vehicle
treated-animals displayed a signiﬁcant increase of iNOS (p<0.01,
Fig. 7b, see densitometric analysis Fig. 7f),whereas iNOS expression
inGC treatmentwas the same as that observed in the in vitromodel.
In particular, the grading scale of protection vs untreated SCI mice
was given by MF (p<0.01) >MPSS (p<0.01) >Dex (non signiﬁcant,
ns) (Fig. 7c–d, respectively. See densitometric analysis Fig. 7f).
3.2.5. GCs counteract SCI-induced PARP-1 activation
Oxidative stress can result in DNA damage, in turn leading to
PARP-1 activation, an enzyme involved in cell death processes as
well as strictly linked to proinﬂammatory mechanisms [23].
Sham mice resulted negative for PARP-1 (Fig. 8a, see den-
sitometric analysis Fig. 8f). On the contrary, compared to this
group, SCI mice group displayed both an increased and signiﬁcant
(p<0.01) expression of thismarker (Fig. 8b, see densitometric anal-
ysis Fig. 8f). In regards to SCI–GC treated mice, we found that MF
demonstrated higher protection capability which avoided PARP-
1 activation (p<0.01) followed by MPSS (p<0.05) and ﬁnally Dex
(not signiﬁcant) (Fig. 8c–d, respectively. See densitometric analy-
M. Galuppo et al. / Pharmacological Research 99 (2015) 316–328 323
Fig. 6. IHC staining for GFAP. SCI-damaged mice (b) have an enhanced and signiﬁcant high GFAP expression when compared with sham animals (a) as well as with SCI +MF
group (c). SCI mice treated with MF (c) display the lower positivity for GFAP, followed by Dex (d) and ﬁnally by MPSS (e). Densitometric quantitative analysis is provide in f.
**p<0.01, ****p<0.0001
sis Fig. 8f). The best efﬁcacy of MF was conﬁrmed by tissue protein
detection in spinal cord extracts (Fig. 8g).
3.2.6. Bax/Bcl-2 unbalanced expression following SCI is
modulated by GC treatments
Apoptotic mechanisms are triggered by traumatic insults to the
spinal with subsequent tissue degeneration.
In the study of the apoptotic pathway through IHC analysis,
we assessed a completely negative staining for Bax (Fig. 9a, see
densitometric analysis Fig. 9f) and a marked positivity for Bcl-2
(Fig. 10a, see densitometric analysis Fig. 10f) in sampled sections
of sham animals. Conversely, SCI mice resulted strongly positive
for Bax (p<0.0001, Fig. 9b, see densitometric analysis Fig. 9f) and
negative for Bcl-2 (p<0.001, Fig. 10b, see densitometric analy-
sis Fig. 10f). Among the different pharmacological treatments, MF
demonstrated a signiﬁcant capacitance in protecting the unbal-
ance between Bax (p<0.0001)/Bcl2 (p<0.001) (Figs. 9 and 10c,
see densitometric analysis Figs. 9 and 10f, respectively), while Dex
(p<0.0001) and MPSS (p<0.001) possessed a lower, although still
signiﬁcant, power against Bax increase (Fig. 9 d and e, see densit-
ometric analysis Fig. 9f) and Bcl-2 degradation (Fig. 10d and e, see
densitometric analysis Fig. 10f). Also western blot detection con-
ﬁrmed a signiﬁcant tissue protection against Bax overexpression
(Fig. 9g).
4. Discussion
Following the acute phase, it is important to underline the
effectiveness of MPSS as the elective choice in the treatment of
inﬂammatory conditions associated with SCI even though side
effects such as depression of the immune system as well as skin
problems must be taken into consideration. However, there is a
gap in the possible chronic management of the disease that at the
moment takes into account baclofen as muscle relaxer and anti-
spastic agent [24]. Nevertheless, although this therapy provides a
reduction of the spasticity, it does not provide protection against
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Fig. 7. IHC staining for iNOS. Sham mice resulted negative for iNOS staining (a). Analyzing sections sampled by SCI mice, we demonstrated that untreated animals display
a signiﬁcant iNOS increasing (b), while there is a differentially modulated iNOS expression by GC treatments. In particular, the grading scale of protection vs untreated SCI
mice is given by MF (c) >MPSS (e) >Dex (d). Densitometric quantitative analysis is provide in f. **p<0.01.
the propagation of secondary damage affecting tissue which sur-
rounds the traumatized area.
The aim of our study consisted in the evaluation of the best pos-
sible treatment for chronic SCI treatment by means of comparison
of different GCs (MPSS, MF and Dex).
Commercially, MF is a topical corticosteroid widely used to
relieve inﬂammation characterized by scaly eruptions and accom-
panied by stinging and itching, such as psoriasis [25] and several
types of dermatitis [26]. Moreover, it is also prescribed in the treat-
ment of asthma [27].
On the another hand, Dex is normally prescribed in combined
therapy with other drugs in the treatment of CNS tumors (mainly
lymphoma) [28,29]. In this study, the in vitro and in vivo compar-
ison of the efﬁcacy of these GCs demonstrated that MF is notably
more effective in the contrasting the diffusion of the so-called per-
ilesional secondary damage. Our conclusions were based on the
evaluation of the different pathways that inclusively represent an
indication for long-term therapy with MF. At present, all three
treatments have demonstrated the ability to modulate inﬂamma-
tory, oxidative as well as apoptotic pathways. However, all the
investigated parameters and evaluatedmarkers demonstrated that
MF was the most effective, whereas Dex and MPSS showed alter-
native results with a factor-by-factor assessable protection degree.
To this end, evidence has proven quite convincing.
Preliminary in vitro experiments performed on LPS-stimulated
murine J774 macrophages have been a useful tool in verifying
whether there could be a differentiallymodulated efﬁcacy of tested
GCs on inhibition of the enzymesmainly involved in the inﬂamma-
tory reaction, such as iNOS and COX-2. Convincing data concerning
the efﬁcacy of MF more than the other GCs were achieved not only
by evaluating its ability in limiting iNOS induction but also, as a
consequence, nitrite production at all tested concentrations. More-
over, MF revealed the higher efﬁcacy not only at lower doses but
also in the control of COX-2 expression. In regards to the histolog-
ical evaluation provided by May Grunwald Giemsa staining, that
gives ameasure of tissue inﬁltrate, the data report a clearly evident
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Fig. 8. GCs counteract SCI-induced PARP-1 activation. Sham mice resulted negative for PARP-1 (a). On the contrary, comparing to this group SCI mice group display an
increased and signiﬁcant expression for this marker (b). About SCI-GC treated mice, we revealed that MF (c) has the best protection capability avoiding PARP-1 activation
followed by MPSS (e) and ﬁnally Dex (d). Densitometric quantitative analysis is provide in f. Western blot analysis of spinal cord protein extracts conﬁrmed the best efﬁcacy
of MF in to counteracting PARP-1 overexpression (g). *p<0.05, ** p<0.01, ND=Not Detectable.
and total protection against WBC inﬁltrates by MF treatment, and
a lower efﬁcacy by Dex or MPSS treatment.
Moreover, we have demonstrated the important role and
involvement of MAPK in the pathogenesis of SCI, as a signaling
pathway of pivotal importance for the downstream mechanisms
in disease progression [30].
Under our experimental conditions, it is interesting to note that
MF signiﬁcantly inhibited ERK1/2 activation, an important path-
way in the pathophysiology of spinal cord cell and tissue injury
following trauma [30]. Moreover, the ERK1/2 signaling pathways
have been found to be involved in microglial/macrophage activa-
tion [31–33] and in free radical production, such as NO [33,34]. This
also translates into a tissue protection from the detrimental action
of oxidative mediators.
In this regard, the role of GFAP in CNS injuries is clear and well
established in literature [35] as marker of astroglial activation and
gliosis. Our evidence shows how the role of GCs, in counteracting
oxidative pathwaymediated by GFAP, arise from a reduced expres-
sion of this marker during SCI neurodegeneration induced by MF
treatment in comparison to Dex and MPSS. Moreover, it is also
demonstrated that GFAP is strongly promoted by NO release [36].
Therefore, it was not a surprise to ﬁnd a correspondent upstream
total absence of iNOS induction particularly following MF treat-
ment.
Moreover, the evaluation of the apoptosis pathway conﬁrmed
the high MF ability in protecting the tissue surrounding the
damaged area. It is well known from the literature that PARP-1
inhibitors ameliorate experimental SCI [37].
Chan et al. reports that inhibiting upregulation of PARP-1 in
the nucleus, in turn, inhibits nuclear translocation of apoptosis-
inducing factors that are related with mitochondrial translocation
of Bax and cytochrome c release [38].
Here we have conﬁrmed that MF, despite probably it does not
act directly on PARP-1 activity, is able to reduce the relatedmecha-
nisms of damage that in not pharmacologically treated SCI animals
produce its activation. Lower activity has been shown by Dex and
MPSS that, however, reduce PARP-1 release in comparison with
untreated SCI. Finally, by avoiding the activation mechanisms of
reparation triggered by serious injury, we investigatedwhetherMF
activity could be related to the nerve tissue protection from the
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Fig. 9. Bax expression following SCI is modulated by GC treatments. A completely negative staining for Bax results in sections sampled by sham animals (a). Conversely, SCI mice are strongly positive (b). MF resulted able to
completely and signiﬁcantly protect tissue by Bax overexpression (c), while Dex (d) andMPSS (e) possess a lower, although still signiﬁcant power. Densitometric quantitative analysis is provide in f. Western blot analysis of spinal
cord protein extracts conﬁrmed the best efﬁcacy of MF in to counteracting Bax overexpression (g). *p<0.05, ***p<0.001, ****p<0.0001, ND=Not Detectable.
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Fig. 10. Bcl-2 expression following SCI is modulated by GC treatments. A marked positivity for Bcl-2 is evident in sections sampled by sham animals (a). Conversely, SCI mice
are negative for Bcl-2 (b), while MF treatment completely and signiﬁcantly protect the tissue by Bcl2 downregulation (c). Dex (d) andMPSS (e) possess a lower, although still
signiﬁcant, power to protect against Bcl-2 degradation.Densitometric quantitative analysis is provide in f. **p<0.01, ***p<0.001, ND=Not Detectable.
altered mitochondrial permeability observed in SCI. Effectively, by
considering the Bax/Bcl-2 balance,MFwas better able thanDex and
MPSS in preserving mitochondrial homeostasis.
5. Conclusions
The present study was designed to evaluate a new therapy in
the management of secondary damage following SCI and its even-
tual use in post-traumatic therapy alone or in association with the
currently used emergency protocolwithMPSS. For this purposewe
have compared the efﬁcacy of MPSS, Dex and MF.
After evaluation of the results, we can conclude that, more than
MPSS and Dex, MF is a better therapy for post-traumatic chronic
treatment of SCI, since it ameliorates different molecular path-
ways at the basis of the damage’s propagation to the surrounding
areas of the injured spinal cord. Since these events are the cause of
severe invalidating consequences in affected patients, the discov-
ery of new treatments becomes of pivotal importance for a more
adequate clinical management of SCI.
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